

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): **May 28, 2021**

**OrthoPediatrics Corp.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**001-38242**

(Commission File Number)

**26-1761833**

(I.R.S. Employer Identification Number)

**2850 Frontier Drive  
Warsaw, Indiana**

(Address of principal executive offices)

**46582**

(Zip Code)

Registrant's telephone number, including area code: **(574) 268-6379**

**Not Applicable**

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of Each Class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, \$0.00025 par value per share	KIDS	Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒

**Item 7.01. Regulation FD Disclosure.**

On May 28, 2021, OrthoPediatrics Corp. (“the Company”) issued a press release announcing the launch of its’ RESPONSE™ Neuromuscular Scoliosis System. This will be the 36th surgical system the Company has launched. RESPONSE™ NeuroMuscular (“RESPONSE – NM”) represents the latest addition to the RESPONSE Scoliosis platform, which is designed to treat pediatric patients. This new system is dedicated to treating neuromuscular scoliosis in pediatrics and was developed in conjunction with pediatric orthopedic surgeons to address the distinct challenges in treating the neuromuscular scoliosis population. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.

The Company does not intend for this Item 7.01 or Exhibit 99.1 to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
<a href="#"><u>99.1</u></a>	<a href="#"><u>Press release dated May 28, 2021, issued by OrthoPediatrics Corp.</u></a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

\* \* \* \* \*

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OrthoPediatrics Corp.

Date: May 28, 2021

By: /s/ Daniel J. Gerritzen  
Daniel J. Gerritzen,  
General Counsel and Secretary



## **OrthoPediatrics Corp. Launches RESPONSE™ Neuromuscular Scoliosis System**

**WARSAW, Indiana, May 28, 2021 — OrthoPediatrics Corp.** (“OrthoPediatrics”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced the launch of its RESPONSE™ Neuromuscular Scoliosis System. This will be the 36<sup>th</sup> surgical system the Company has launched.

The system received FDA 510(k) clearance in 2020, and the Company has been preparing for a full-scale domestic launch this summer. RESPONSE Neuromuscular (“RESPONSE NM”) represents the latest addition to the RESPONSE Scoliosis platform, which is designed to treat pediatric patients. This new system is dedicated for the treatment of neuromuscular scoliosis and was developed in conjunction with pediatric orthopedic surgeons to address the distinct challenges in treating a unique patient population. Building on the base of the Company’s RESPONSE Spine System, RESPONSE NM features a complete set of implants and instruments with innovative attributes that simplify insertion and specific options to address extreme hyperlordosis and sacral/pelvic fixation.

Dr. Scott Luhmann, Pediatric Orthopedic Surgeon and Chief of Staff at Shriner’s Hospital for Children in St. Louis, Missouri was part of the design team, commenting, “Neuromuscular scoliosis patients can present with a wide array of extreme 3-dimensional deformities, which can require highly individualized and complicated surgical treatment. The addition of the Neuromuscular Scoliosis System to the OrthoPediatrics RESPONSE offering was designed to improve the speed and efficacy of the instrumentation, correction and stabilization of these complicated deformities, with the aim of optimizing outcomes. This now makes the OP RESPONSE system the ideal one for all types of pediatric spinal deformity.”

The RESPONSE NM system also works in conjunction with other products in the OrthoPediatrics Scoliosis franchise, including the BandLoc Sublaminar banding system, and FIREFLY 3D printed pedicle screw guides. OrthoPediatrics is the exclusive distributor for Mighty Oak Medical’s FIREFLY technology in children’s hospitals across the United States.

OrthoPediatrics’ Vice President of Scoliosis, Jeff Smithey, stated, “We are excited about the launch of the RESPONSE NM and this first of its kind offering completely focused on implants and instruments for treating neuromuscular scoliosis. Our platform of neuromuscular solutions further demonstrates how OrthoPediatrics is uniquely focused on development of products that help pediatric orthopedic surgeons and their patients around the world.”

### **About OrthoPediatrics Corp.**

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 36 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering span trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 45 countries outside the United States. For more information, please visit [www.orthopediatrics.com](http://www.orthopediatrics.com).

### **Investor Contacts**

Matt Bacso, CFA  
Gilmartin Group

[Matt.bacso@gilmartinir.com](mailto:Matt.bacso@gilmartinir.com)



TRAUMA & DEFORMITY



SPINE



SPORTS MEDICINE



CLINICAL EDUCATION

2850 Frontier Drive  
Warsaw, Indiana 46582  
[www.orthopediatrics.com](http://www.orthopediatrics.com)

TOLL-FREE 877.268.6339  
PHONE 574.268.6379  
FAX 574.269.3692